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ABSTRACT
Previous studies revealed that inflammatory biomarkers have a role in the 
clinical outcomes of acute coronary syndromes (ACS) and also in prediction 
of cardiovascular events using GRACE score. Resistin, a recently identified 
inflammatory biomarker, also has a role in clinical outcomes of ACS but 
its role related to GRACE score risk stratification is unknown. Three risk 
stratifications of ACS based on GRACE scores were used i.e. low, intermediate, 
and high.  Some studies reported that inflammatory biomarkers have a role 
in cardiovascular events of patients with low risk GRACE scores, but their role 
in the patients with intermediate risk still needs to be elucidated. This study 
aimed to investigate the role of resistin in cardiovascular events of ACS patients 
with intermediate risk GRACE score. This was an observational study using a 
cross-sectional design involving sixty-three patients with ACS who fulfilled the 
inclusion and exclusion criteria. Blood samples were drawn 24 h after onset. 
Resistin level was analyzed and classified according to its median values. 
The cardiovascular event was defined as mortality, ischemic events, acute 
heart failure or arrhythmia during hospitalization. The result showed that 
cardiovascular events were significantly higher in patients with resistin levels 
higher than median i.e. 23.8% compared to those with resistin levels similar or 
lower than median i.e. 11.1% (OR 3.348, 95%CI: 1.125-10.007 p=0.027). It can be 
concluded high resistin level is associated with an increase of cardiovascular 
events of ACS with intermediate risk GRACE score.
ABSTRAK
Penelitian sebelumnya menunjukkan bahwa penanda inflamasi berperan 
pada luaran klinik sindrom koroner akut (SKA) dan juga dalam memprediksi 
kejadian kardiovaskular menggunakan skor GRACE. Resistin sebagai salah 
satu penanda inflamasi juga berkaitan dengan kejadian kardiovaskular 
pada SKA namun perannya terhadap kejadian kardiovaskular berdasarkan 
skor GRACE belum pernah diteliti. Berdasarkan skor GRACE, SKA dibedakan 
dalam tiga stratifikasi risiko yaitu risiko rendah, sedang dan tinggi, Beberapa 
penelitian telah melaporkan penanda inflamasi berperan dalam kejadian 
kardiovaskular pada SKA dengan skor GRACE risiko rendah, tetapi perannya 
pada SKA dengan skor GRACE risiko sedang perlu dibuktikan. Penelitian ini 
bertujuan untuk mengkaji peran resistin sebagai salah satu penanda inflamasi, 
terhadap kejadian kardiovaskular pada SKA dengan skor GRACE risiko sedang. 
Penelitian ini merupakan penelitian observasi dengan rancangan potong 
lintang yang melibatkan 63 pasien SKA yang memenuhi kriteria inklusi 
dan eksklusi. Pengambilan sampel darah untuk pengukuran kadar resistin 
dilakukan dalam 24 jam pasca awitan serangan. Kadar resistin diukur dan 
dikelompokkan berdasarkan nilai mediannya. Kejadian kardiovaskular 
didefinisikan sebagai kematian, kejadian iskemik, gagal jantung akut dan 
aritmia yang terjadi selama perawatan di rumah sakit. Hasil penelitian 
menunjukkan kejadian kardiovaskular lebih tinggi secara bermakna pada 
kelompok kadar resistin di atas median yaitu 23,8% dibandingkan kelompok 
kadar resistin sama atau di bawah median yaitu 11,1% (RO 3,348, 95% IK 1,125-
10,007 p=0,027). Dari penelitian ini dapat disimpulkan bahwa kadar resistin 
tinggi berkaitan dengan kenaikan kejadian kardiovaskular pada populasi SKA 
dengan skor GRACE risiko sedang.
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INTRODUCTION
Inflammatory markers have been 
proven to have role in cardiovascular 
events of acute coronary syndrome 
(ACS).1,2 Resistin, an inflammatory 
marker recently found to be related to 
ACS, is a cysteine rich protein formerly 
found in mouse’s adipocytes, correlated 
with insulin resistance.3 It was stated 
that resistin had a role in cardiovascular 
events of ACS, however, there are still 
inconclusive.4 Moreover, in the role 
pertaining to clinical outcomes of ACS, 
an inflammatory marker should prove 
not only its independent role towards 
cardiovascular events but also its role 
towards cardiovascular events in ACS 
according to some risk stratification 
methods.5
Among risk stratification methods 
in ACS, the guidelines recommended the 
application of the global registry of acute 
coronary events (GRACE) score.6 The 
validation study of GRACE score reported 
that there is a gap of cardiovascular 
events incidence between GRACE 
score classifications. The prediction 
performance of intermediate and low 
risk was not as accurate as high risk. 
This was related to the possibility of 
other factors that affect the outcome, 
and one of them is the inflammatory 
biomarker.7,8 Beygui et al.9 reported 
that the inflammatory biomarker had 
additional prognostic value in the low-
risk GRACE score. Therefore, there 
exists the need to investigate whether 
inflammatory markers such as resistin 
had an additional role in intermediate 
GRACE scores. This study aimed to 
evaluate whether resistin has a role in 
cardiovascular events in patients with 
ACS with intermediate-risk GRACE score.
MATERIALS AND METHODS
Population and samples
This was an observational study 
with a cross-sectional design conducted 
in the Cardiovascular Unit, Department 
of Cardiology and Vascular Medicine, 
Faculty of Medicine, Public Health and 
Nursing, Universitas Gadjah Mada/Dr. 
Sardjito General Hospital, Yogyakarta, 
Indonesia for 6 months from October 
2013 to April 2014. The inclusion 
criteria of this study were patients 
with ACS who have intermediate risk 
GRACE score, score 109-140 for non-
ST elevation acute coronary syndrome 
(NSTEACS) and score 126-154 for ST 
elevation myocardial infarction (STEMI) 
and came to the hospital with onset less 
than 24 h and no previous definitive 
therapy for ACS. Definitive therapy was 
defined as anticoagulant or reperfusion 
given to the subject according to ACS 
guidelines.6,10 The exclusion criteria 
were patients with sepsis, chronic renal 
disease, thyroid disease, chronic heart 
failure malignancy, underwent TZD 
(thiazoliendidione) therapy, underwent 
glucocorticoid therapy, concomitant 
diabetic complications, DKA (diabetic 
ketoacidosis) and HHS (hyperglycemia 
hyperosmolar state), stroke, pregnancy, 
cardiomyopathy, valvular heart disease, 
or in chronic anticoagulant therapy.
Resistin measurement
Serum resistin level was measured 
from venous blood taken within 24 h 
after symptoms onset. Two milliliters 
of venous blood sample was placed in 
EDTA vacutainer then being centrifuged 
at 1,000 G in 15 min and then serum was 
preserved in several aliquots and placed 
in -80º until analysis. The serum resistin 
level was analyzed using ELISA (enzyme 
link immunosorbent assay) with reagent 
kit human resistin R&D System, USA®.
Research protocols
Patients with ACS who met the 
inclusion and exclusion criteria and 
willing to participate in this study were 
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given definitive therapy according to 
the guidelines and hospital protocol. 
The primary outcome of this study was 
cardiovascular events which consisted 
of in hospital mortality, arrhythmia, 
acute heart failure and ischemic events. 
Ischemic events in this study were 
defined as persistent or residual angina, 
failed fibrinolysis, and reinfarction.
Cardiovascular events were 
observed during hospitalization in 
each subject with a specific time frame, 
immediately after reperfusion therapy 
for STEMI, one h after the first dose of 
unfractionated heparin (UFH) or six h 
after first dose low molecular weight 
heparin (LMWH) or 3 h after first dose 
of fondaparinux for NSTEACS and STEMI 
subjects who did not meet reperfusion 
criteria. Observation was stopped if the 
first cardiovascular event occurred but 
if no cardiovascular event occurred, 
observation was continued until 
discharge (FIGURE 1).
FIGURE 1. Research protocol
Statistical analysis
Categorical variables were analyzed 
with chi-squared and Fisher’s exact tests. 
Continuous variables were analyzed 
using student t or Mann-Whitney U tests. 
This study applied 95% confidence level 
(CI) with p value <0.05 to be cosidered as 
a significant result. SPSS Program 15.0 
(IBM Corp., Chicago) was applied for 
statistical analysis.
Ethical clearance
This study has been approved by 
the Medical and Health Research Ethic 
Committee, of the Faculty of Medicine, 
Public Health and Nursing, Universitas 
Gadjah Mada /Dr. Sardjito Hospital 
General Hospital on September 6th, 2013.
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RESULTS
Seventy two patients with ACS who 
met the inclusion were recruited. Nine 
patients were excluded due to stroke, 
chronic heart failure, malignancy, 
chronic kidney disease. One patient 
with an indication of intervention but it 
had not been performed. Therefore, 63 
patients consisted of 39 patients (62%) 
with STEMI, and 24 patients (38 %) with 
NSTEACS. participated in this study. 
The distribution of resistin levels 
is presented in the following histogram 
(FIGURE 2). The mean resistin level in 
this study was 1.97±1.69 ng/mL ranging 
between 0.71 to 9.05 ng/mL and the 
median was 1.36 ng/mL.
FIGURE 2. Distribution of serum resistin level in ACS with 
intermediate risk GRACE score.
FIGURE 2 shows the distribution 
of resistin among patients involved in 
this study. An abnormal distribution 
of resistin where the curve with right 
skewness was observed. Based on this 
result, the resistin level was classified 
into two groups according to its median 
i.e the low level group which the resistin 
level similar or lower than the median 
resistin level and the high level group 
which the resistin level higher than the 
median resistin level. TABLE 1 presents 
baseline characteristics of patients 
according to the resistin level. 
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•	Age (mean ± SD years) 57.7± 8.2 59.6 ± 8.0 0.360
•	Male [n (%)] 27 (84.4) 21 (67.7)
0.121
•	Female [n (%)] 5 (15.6) 10 (32.3)
•	BMI [kg/m2 (median-range] 22.5 (17.6-28) 23.1 (17.7-36.7) 0.740
Risk factors
•	Smoker [n (%)] 12 (19) 7 (11.1) 0.363
•	Dyslipidemia [n (%)] 22 (34.9) 18 (28.6) 0.378
•	Hypertension [n (%)] 19 (30.2) 20 (31.7) 0.674
•	Diabetes mellitus [n (%)] 9 (14.3) 7 (11.1) 0.613
•	Family history [n (%)] 2 (3.2) 0 0.157
Medical history 
•	MI (n,%) 6 (7.9) 5 (9.5) 0.523
•	PCI (n,%) 3 (4.8) 1 (1.6) 0.319
•	Onset [hours (median-range)] 6 (1-24) 4.5 (2-24) 0.507
Therapy before admission 
•	 Insulin [n (%)] 4 (6.3) 4 (6.3) 0.628
•	CCB dihydropyridine [n (%)] 0 1(1.6) 0.492
•	ACEi [n (%)] 2 (3.2) 2 (3.2) 0.681
•	 \Statin [n (%)] 4 (6.3) 0 0.113
Laboratory
•	Creatinine (mean±SD mg/dL) 0.9±0.27 1.08±0.33 0.222
•	Blood glucose on admission [mg/
ml (median-range)]
135 (80-387) 137 (73-468) 0.478
Definitive therapy
•	Thrombolytics [(n (%)] 7 (11.1) 13 (20.6) 0.087
•	PCI [n (%)] 11 (17.5) 9 (14.3) 0.649
•	Heparin [n (%)] 30 (47.6) 29 (46) 0.681
Medications during hospitalization
•	Beta blockers [n (%)] 26 (42.3) 24 (38.1%) 0.707
•	Statin [n (%)] 31 (49.2) 31 (49.2%) 0.508
•	ACEi [n (%)] 22 (35.5) 19 (30.6%) 0.652
•	ARB [ n (%)] 5 (7.9) 4 (6.3%) 0.521
BMI: body mass index; MI: myocardial infarction; PCI: percutaneous coronary 
intervention; CCB: calcium channel blocker; ACEi: angiotensin-converting enzyme 
inhibitor; ARB: angiotensin receptor blocker; SD: standard deviation
There were more male subjects than 
females in this study with a mean of 59 
y.o. Hypertension and dyslipidemia were 
dominant as risk factors for all subjects. 
Baseline characteristics showed no 
significant differences of demography, 
risk factors, previous therapy, laboratory, 
definitive therapy, and medication 
during hospitalization between the two 
resistin groups.
During observation, there were 
22 (34.9%) cardiovascular events that 
occurred during hospitalization and the 
majorities were ischemic events (86.4%). 
There was no in hospital mortality during 
the observation, 2 (9.1%) subjects had 
acute heart failure (9.1%,) and 1 (4.5%) 
subject had arrhythmia ventricular 
tachycardia (FIGURE 3). The ischemic 
events that occurred in this study were 
predominately residual angina (20.3%) 
followed by failed thrombolysis and 
reinfarction (FIGURE 4).
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FIGURE 3. Cardiovascular events in acute coronary syndrome with 
Intermediate GRACE Score.
FIGURE 4. Proportion of ischemic events
The differences in cardiovascular 
events between the two resistin groups 
were analyzed by using chi-squared test 
(TABLE 2). The result showed that the 
resistin level is significantly associated 
with cardiovascular events in ACS with 
intermediate risk GRACE score (p= 0.027).
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event (+) [n 
(%)]
Cardiovascular 





15 (23.8) 16 (25.4)
3.348 1.120-10.007 0.027Resistin ≤ median
(≤1.36 ng/mL)
n=32
7 (11.1) 25 (39.7)
n 22 (24.9) 41 (65.1)
OR: odds ratio, CI: confidence interval
The cardiovascular events were 
higher in subjects with the high resistin 
level compared with those with the low 
resistin level for the ACS population in 
this study with odds ratio (OR) 3.348 (95% 
CI: 1.120-10.007; p=0.027). Furthermore, 
analysis was conducted to evaluate the 
difference of cardiovascular events 
between the two resistin groups in the 
sub populations of STEMI and Non-ST 
Elevation ACS (NSTEACS) (TABLE 3 and 
4). In the STEMI subpopulation, the 
cardiovascular events were higher in 
the high resistin level group compared 
to those the low resistin level according 
to its median with OR 5.564 (95% CI: 
1.255-25.294; p=0.02). The opposite was 
found in the NSTEACS subpopulation, 
indicating that there were no differences 
in cardiovascular events between the 
both resistin groups (p=0.698).




event (+) [n (%)]
Cardiovascular 










10 (25.6) 13 (33.3)
n 23 (59.0) 16 (41.0)
OR: odds ratio, CI: confidence interval
TABLE 4. Resistin and cardiovascular events in subpopulation NSTEACS with 
intermediate risk GRACE score.
Variables
Cardiovascular 
event (+) [n (%)]
Cardiovascular 










4 (16.7) 12 (50.0)
n 8 (25.0) 18 (75.0)
OR: odds ratio, CI: confidence interval
254
J Med Sci, Volume 53, Number 3, 2021 July: 247-256
DISCUSSION
The main results of this study showed 
that there was a significant difference 
in cardiovascular events between the 
bot resistin groups. Patients with high 
resistin level had more cardiovascular 
events compared to those with low 
resistin level. This finding was consistent 
in the STEMI subpopulation and in all 
subjects who had intermediate GRACE 
Score.
Based on findings from a study 
conducted by Correia et al.,11 in 2010, 
inflammatory markers have an additional 
prognostic value to GRACE score. The 
study established a scoring model of 
inflammatory markers and added to 
GRACE score, this additional scoring 
had net reclassification improvement 
of 13%. Based on Lubos et al.,12 in 2007, 
high resistin level was correlated to 
1.19 times (95%CI: 0.98-1.45) increment 
of cardiovascular death however that 
result was statistically insignificant 
with p=0.08. Furthermore, Lee et al.,13 
in 2009 conducted a prognostic study 
with time of follow-up at 12 months and 
concluded that resistin was significantly 
correlated with 1.16 (95% CI: 1.12-2.28) 
times increment of all causes of death 
with p=0.01 but there was no significant 
correlation with cardiovascular death in 
the patients with ACS. Discrepancies of 
our finding with those previous findings 
was likely because there was no in hospital 
mortality events observed, and in our 
study the most dominant cardiovascular 
event was ischemia particularly residual 
angina. These discrepancies in mortality 
finding could be due to differences in the 
population of study, since in our study 
we specifically chose subjects with ACS 
with intermediate GRACE score.
Regarding our finding of ischemia 
as the highest cardiovascular event, 
according to literature, high resistin would 
increase oxidative stress and decrease 
endothelial nitric oxide (eNOS), which 
is a coronary vasodilator. Additionally, 
resistin  is also known to have a role 
in decreasing coronary sensitivity to 
the relaxation effect of bradykinin This 
would enhance vasoconstriction and 
decrease myocardial oxygen supply 
contributing to ischemia and angina.14,15 
Furthermore, resistin was found to 
have a role in exaggerating platelet 
aggregation and thrombosis.16-18
Differences in the cardiovascular 
events between STEMI and NSTEACS still 
need to be confirmed by further research, 
whether it was due to differences of 
resistin level among subsets of ACS19,20 
or to determine if there were differences 
of resistin level in the coronary artery. 
This was postulated by Langheim et 
al.,21 in 2010 proposing that there was 
the secretion of resistin from epicardial 
adipose tissue.
One limitation of this study was the 
unavailability of other inflammatory 
markers’ data such as C-Reactive 
Protein, Interleukin 6, and Tumor 
Necrosis Factor-α for comparison or as 
confounding factors to analyze the role 
of resistin in ACS.
CONCLUSIONS
Serum resistin level is associated 
with higher cardiovascular events in ACS 
patients with intermediate risk GRACE 
score.
ACKNOWLEDGMENTS
Authors would like to thank all 
staff and residents of the Department 
of Cardiology and Vascular Medicine, 
Faculty of Medicine, Public Health and 
Nursing, Universitas Gadjah Mada/Dr. 
Sardjito General Hospital, Yogyakarta 
and the Laboratory of Biology Molecular, 
Faculty of Medicine, Public Health and 
Nursing, Universitas Gadjah Mada, 
Yogyakarta.
255
Gumilang RA, et al., Resistin associated with higher...
REFERENCES
1. Battistoni A, Rubattu S, Volpe 
M. Circulating biomarkers 
with preventive, diagnostic 
and prognostic implications in 
cardiovascular diseases. Int J Cardiol 
2012; 157(2):160-8.
h t t p s : / / d o i . o r g / 1 0 . 1 0 1 6 / j .
ijcard.2011.06.066
2. Blake GJ, Ridker PM. C-Reactive 
protein and other inflammatory 
risk markers in acute coronary 
syndromes. J Am Coll Cardiology 
2003; 41(4 Suppl S):37S-42S.
https : / /doi .org/10.1016/S0735-
1097(02)02953-4
3. Steppan CM, Lazar MA. Resistin 
and obesity-associated insulin 
resistance. Trends Endocrinol Metab 
2002; 13(1):18-23. 
ht tps : / /doi .org/10.1016/S1043-
2760(01)00522-7
4. Ding Q, White SP, Ling C, Zhou W. 
Resistin and cardiovascular disease. 
Trends Cardiovasc Med 2011; 
21(1):20-7.
https://doi.org/10.1016/j.tcm.2012.01.004
5. Correia LCL, Andrade BB, Borges VM, 
Clarencio J, Bittencourt AP, Freitas R, 
et al. Prognostic value of cytokines 
and chemokines in addition to the 
GRACE score in non-ST-elevation 
acute coronary syndromes. Clin 
Chima Acta 2010; 411(7-8):540-5. 
https://doi.org/10.1016/j.cca.2010.01.011
6. O’Gara PT, Kushner FG, Ascheim DD, 
Casey DE Jr, Chung MK, de Lemos 
JA, et al. 2013 ACCF/AHA guideline 
for the management of ST-elevation 
myocardial infarction: a report of 
the American College of Cardiology 
Foundation/American Heart 
Association Task Force on Practice 
Guidelines. J Am Coll Cardiol 2013; 
61(4):e78-140. 
h t t p s : / / d o i . o r g / 1 0 . 1 1 6 1 /
CIR.0b013e3182742cf6
7. Elbarouni B, Goodman SG, Yan RT, 
Welsh RC, Kornder JM, DeYoung JP, et 
al. Validation of the Global Registry 
of Acute Coronary Event (GRACE) 
risk score for in-hospital mortality 
in patients with acute coronary 
syndrome in Canada. Am Heart J 
2009; 158(3):392-9. 
https://doi.org/10.1016/j.ahj.2009.06.010
8. Granger CB. Predictors of hospital 
mortality in the Global Registry of 
Acute Coronary Events. Arch Intern 
Med 2003; 163(19):2345-53. 
h t t p s : / / d o i . o r g / 1 0 . 1 0 0 1 /
archinte.163.19.2345
9. Beygui F, Silvain J, Pena A, Bellemain-
Appaix A, Collet JP, Drexler H, et al. 
Usefulness of biomarker strategy to 
improve GRACE score’s prediction 
performance in patients with non–
ST-segment elevation acute coronary 
syndrome and low event rates. Am J 
Cardiol 2010; 106(5):650-8. 
h t t p s : / / d o i . o r g / 1 0 . 1 0 1 6 / j .
amjcard.2010.04.019
10. Jneid H. The 2012 ACCF/AHA Focused 
Update of the Unstable Angina/Non-
ST-Elevation Myocardial Infarction 
(UA/NSTEMI) guideline: a critical 
appraisal. Methodist DeBakey 
Cardiovasc J 2012; 8(3):26-30. 
h t t p s : / / d x . d o i .
org/10.14797%2Fmdcj-8-3-26
11. Correia LCL, Freitas R, Bittencourt 
AP, Souza AC, Almeida MC, Leal J, et 
al. [Prognostic value of GRACE scores 
versus TIMI score in acute coronary 
syndromes]. Arq Bras Cardiol 2010; 
94(5):613-9. 
ht tps : / /doi .org /10 .1590/s0066-
782x2010005000036
12. Lubos E, Messow CM, Schnabel 
R, Rupprecht HJ, Espinola-Klein 
C, Bickel C, et al. Resistin, acute 
coronary syndrome and prognosis 
results from the AtheroGene study. 
Atherosclerosis 2007; 193(1):121-8.
h t t p s : / / d o i . o r g / 1 0 . 1 0 1 6 / j .
atherosclerosis.2006.05.039
13. Lee SH, Ha JW, Kim JS, Choi EY, Park 
S, Kang SM, et al. Plasma adiponectin 
and resistin levels as predictors 
256
J Med Sci, Volume 53, Number 3, 2021 July: 247-256
of mortality in patients with acute 
myocardial infarction: data from 
infarction prognosis study registry. 
Coron Artery Dis 2009; 20(1):33-9. 
h t t p s : / / d o i . o r g / 1 0 . 1 0 9 7 /
mca.0b013e328318ecb0
14. Chen C, Jiang J, Lu JM, Chai H, Wang 
X, Lin PH, et al. Resistin decreases 
expression of endothelial nitric oxide 
synthase through oxidative stress in 
human coronary artery endothelial 
cells. Am J Physiol Heart Circ Physiol 
2010; 299(1):H193-201.
h t t p s : / / d o i . o r g / 1 0 . 1 1 5 2 /
ajpheart.00431.2009
15. Kougias P, Chai H, Lin PH, Lumsden 
AB, Yao Q, Chen C. Adipocyte-derived 
cytokine resistin causes endothelial 
dysfunction of porcine coronary 
arteries. J Vasc Surg 2005; 41(4):691-8.
https://doi.org/10.1016/j.jvs.2004.12.046
16. Calabro P, Cirillo P, Limongelli G, 
Maddaloni V, Riegler L, Palmieri 
R, et al. Tissue factor is induced by 
resistin in human coronary artery 
endothelial cells by the NF-kB-
dependent pathway. J Vasc Res 2011; 
48(1):59-66. 
https://doi.org/10.1159/000318775
17. Chen N, Wang X, Zhang1 Q, Qiu1 W, 
Yin J, Lin J, et al. Resistin stimulates 
platelet P-selectin expression via p38 
MAPK signal pathway. Circulation 
2011; 124.
18. Fang WQ, Zhang Q, Peng YB, Chen M, 
Lin XP, Wu JH, et al. Resistin level is 
positively correlated with thrombotic 
complications in Southern Chinese 
metabolic syndrome patients. J 
Endocrinol Invest 2011; 34(2):e36-42. 
https://doi.org/10.1007/bf03347059
19. Qiao XZ, Yang YM, Xu ZR, Yang 
LA. Relationship between resistin 
level in serum and acute coronary 
syndrome or stable angina pectoris. 
J Zhejiang Univ Scie B 2007; 8(12):875-80. 
h t t p s : / / d x . d o i .
org/10.1631%2Fjzus.2007.B0875
20. Chu S, Ding W, Li K, Pang Y, Tang 
C. Plasma resistin associated with 
myocardium injury in patients with 
acute coronary syndrome. Circ J 
2008; 72(8):1249-53. 
https://doi.org/10.1253/circj.72.1249
21. Langheim S, Dreas L, Veschini L, 
Maisano F, Foglieni C, Ferrarello 
S, et al. Increased expression and 
secretion of resistin in epicardial 
adipose tissue of patients with acute 
coronary syndrome. Am J Physiol 
Heart Circ Physiol 2010; 298(3):H746-53. 
h t t p s : / / d o i . o r g / 1 0 . 1 1 5 2 /
ajpheart.00617.2009
